Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry | Aplastic Anemia & MDS International Foundation Return to top.
  1. Education
  2. Research Articles
  3. Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry

Journal Title: 
Leukemia
Primary Author: 
Dinmohamed AG
Author(s): 
Dinmohamed AG, van Norden Y, Visser O, Posthuma EF, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Jongen-Lavrencic M
Original Publication Date: 
Tuesday, September 15, 2015
Full Article on PubMed: 
https://www.ncbi.nlm.nih.gov/pubmed/26369829/

No abstract available.

Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Share with addtoany.com.